Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $273 Price Target

Benzinga Newsdesk www.benzinga.com Negative 90.4%

Neg 90.4% Neu 0% Pos 0%

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $273 price target.

Comments

No comments yet. Be the first!